Table 2.
Tyrosine kinase resistance mutations and TP53 mutations in the entire cohort (left column) and in ALK and ROS1-patients (middle and right column).
| All patients (n = 52) | ALK-positive (n = 37) | ROS1-positive (n = 15) | |
|---|---|---|---|
| Assessment of specific tyrosine kinase mutations (NGS), n (%) | 26 (50.0) | 23 (62.2) | 3 (20.0) |
| Tyrosine kinase mutation* | 15 (57.7) | 13 (56.5) | 2 (66.6) |
| V1149A | 1 | ||
| C1156Y | 2 | ||
| I1171N | 1 | ||
| F1174V | 1 | ||
| L1196M | 4 | ||
| G1202R | 8 | ||
| D1203N | 1 | ||
| G1269A | 2 | ||
| G2032R | 2 | ||
| No tyrosine kinase mutation | 11 (42.3) | 10 (43.5) | 1 (33.3) |
| Assessment of TP53 mutations, n (%) | 41 (78.8) | 31 (83.8) | 10 (66.7) |
| TP53 mutation | 11 (26.8) | 5 (16.1) | 6 (60.0) |
| No TP53 mutation | 28 (68.3) | 25 (80.7) | 3 (30.0) |
| TP53 not evaluable | 2 (4.9) | 1 (3.2) | 1 (10.0) |
*
compound mutations (n = 6): L1196M-based: +I1171N, +F1174V, +D1203N; G1202R-based: +V1149A+L1196M, +C1156Y, +G1269A.
NGS, next-generation sequencing.